Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
Romiplostim
KYOWA HAKKO KIRIN (SINGAPORE) PTE. LTD.
B02BX04
Romiplostim 375μg/vial (deliverable amt 250μg/vial)
INJECTION, POWDER, FOR SOLUTION
SUBCUTANEOUS
Prescription Only
Patheon Italia S.p.A
2012-02-08
Annex B1 (Proposed/clean) Page 1 of 13(DRAFT PI_SIN_19 SEP 12) 1. NAME OF THE MEDICINAL PRODUCT Nplate 250 micrograms powder for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 250 µg of romiplostim. After reconstitution, a deliverable volume of 0.5 ml solution contains 250 µg of romiplostim (500 µg/ml). An additional overfill is included in each vial to ensure that 250 µg of romiplostim can be delivered. Romiplostim is produced by recombinant DNA technology in _Escherichia coli_ (_E. coli_). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for solution for injection. This powder is white. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Nplate is indicated for adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Nplate may be considered as second line treatment for adult non-splenectomised patients where surgery is contra-indicated. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should remain under the supervision of a physician who is experienced in the treatment of haematological diseases. Posology Nplate should be administered once weekly as a subcutaneous injection. Initial dose The initial dose of romiplostim is 1 µg/kg based on actual body weight. _Dose calculation _ Initial or subsequent once weekly dose: Weight* in kg x Dose in µg/kg = Individual patient dose in µg Volume to administer: Dose in µg x 1 ml . 500 µg = Amount to inject in ml Example 75 kg patient is Read the complete document